Q1 2023 EPS Estimates for Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Raised by Analyst

Posted by Defense World Staff on Apr 7th, 2023

Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Get Rating) – Brookline Capital Management raised their Q1 2023 earnings per share estimates for Oncternal Therapeutics in a report released on Monday, April 3rd. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings of ($0.16) per share for the quarter, up from their prior estimate of ($0.22). Brookline Capital Management has a “Hold” rating on the stock. The consensus estimate for Oncternal Therapeutics’ current full-year earnings is ($0.93) per share. Brookline Capital Management also issued estimates for Oncternal Therapeutics’ Q2 2023 earnings at ($0.15) EPS, Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.12) EPS, FY2023 earnings at ($0.54) EPS and FY2024 earnings at ($0.43) EPS.

A number of other equities analysts have also weighed in on ONCT. Maxim Group lowered shares of Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. StockNews.com assumed coverage on Oncternal Therapeutics in a research report on Thursday, March 16th. They set a “sell” rating on the stock. Cantor Fitzgerald cut shares of Oncternal Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday. Brookline Capital Acquisition reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research note on Tuesday. Finally, Oppenheimer cut shares of Oncternal Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.77.

Oncternal Therapeutics Price Performance

Shares of NASDAQ:ONCT opened at $0.28 on Thursday. The stock’s fifty day moving average price is $0.88 and its 200-day moving average price is $0.97. Oncternal Therapeutics has a 1 year low of $0.27 and a 1 year high of $1.87. The company has a market cap of $16.16 million, a P/E ratio of -0.33 and a beta of 1.57.

Hedge Funds Weigh In On Oncternal Therapeutics

Several hedge funds have recently made changes to their positions in the company. Mirabella Financial Services LLP acquired a new position in Oncternal Therapeutics during the first quarter valued at $38,000. Prudential Financial Inc. acquired a new stake in shares of Oncternal Therapeutics during the 2nd quarter valued at about $32,000. Waypoint Capital Advisors LLC acquired a new position in Oncternal Therapeutics in the 4th quarter worth about $38,000. Virtu Financial LLC acquired a new position in shares of Oncternal Therapeutics during the 2nd quarter worth approximately $48,000. Finally, CI Private Wealth LLC acquired a new stake in Oncternal Therapeutics in the 4th quarter valued at $150,000. 16.66% of the stock is owned by institutional investors and hedge funds.

About Oncternal Therapeutics

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.